Rafael (NYSE:RFL) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Rafael (NYSE:RFL) to a hold rating in a research report report published on Saturday morning.

Separately, Weiss Ratings raised Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Rafael currently has a consensus rating of “Sell”.

Rafael Price Performance

RFL opened at $2.11 on Friday. The business has a 50 day simple moving average of $2.16 and a 200-day simple moving average of $1.58. The stock has a market capitalization of $109.72 million, a P/E ratio of -3.10 and a beta of 0.29. Rafael has a 12 month low of $1.12 and a 12 month high of $3.96.

Institutional Investors Weigh In On Rafael

Several institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its position in shares of Rafael by 59.1% in the first quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock valued at $111,000 after acquiring an additional 33,111 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Rafael by 25.4% during the 4th quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock valued at $526,000 after buying an additional 90,417 shares during the period. Citadel Advisors LLC grew its position in Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after acquiring an additional 41,335 shares during the period. Vanguard Group Inc. grew its holdings in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after purchasing an additional 133,024 shares during the period. Finally, Cable Car Capital LP acquired a new stake in shares of Rafael in the second quarter worth $173,000. 11.30% of the stock is currently owned by hedge funds and other institutional investors.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.